Is More M&A On The Way For Large-Cap Biotechs?
Following the recently-announced Teva Pharmaceutical TEVA 2.55% buyout of Allergan Plc AGN 2.7%, RBC Capital Markets analyst Michael Yee released a report discussing the potential for large-cap biotech companies to become buyout targets for specialty pharmaceutical companies. According to Yee, no such deal would even be feasible until “well into 2016.”